Nuvalent Stock Soars on $10.6 Billion GSK Buyout

Nuvalent is surging 38.9% in premarket to $122.88 after GSK agreed to acquire the cancer drug developer in an all-cash deal valued at approximately $10.6 billion. The transaction is a significant biotech M&A event and provides a clear premium to shareholders. The move is likely to materially reprice NUVL and draw broader attention to the oncology pipeline acquisition space.

Analysis

Nuvalent is surging 38.9% in premarket to $122.88 after GSK agreed to acquire the cancer drug developer in an all-cash deal valued at approximately $10.6 billion. The transaction is a significant biotech M&A event and provides a clear premium to shareholders. The move is likely to materially reprice NUVL and draw broader attention to the oncology pipeline acquisition space.